NetraMark is a Toronto-based machine learning software company founded by Joseph Geraci in 2015.
Netramark's services are composed of its three proprietary technologies: NetraplayNetraPlay, NetraAI, and DeepCrush. NetraplayNetraPlay functions as an interface that allows users to determine and manipulate data inputs and outputs through the use of augmented intelligence. NetraAI is a machine learning tool intended to analyze small datasets, although when DeepCrush's functionality is activated, it is able to analyze datasets of all sizes and classify them based on identified correlates. In Netramark's NetraPharma venture, all of these technologies are employed alongside NetraHealthAtlas, a repository of pharmacological-related data.
Netramark is a company developing machine learning-based software-as-a-service (SaaS). It was founded in 2015 by Joseph Geraci and Richard Brooks. The company also entered into a joint venture with Juvenescence AI in 2018 under the name of NetraPharma, which focuses on establishing a computational drug discovery platform. Netramark is headquartered in TorontoToronto, Ontario, Canada.
Netramark is a company developing machine learning-based software-as-a-service (SaaS). It was founded in 2015 by Joseph Geraci and Richard Brooks. The company also entered into a joint venture with Juvenescence AI in 2018 under the name of NetraPharma, which focuses on establishing a computational drug discovery platform. Netramark is headquartered in Toronto, Ontario, Canada.
Netramark is a company developing machine learning-based software-as-a-service (SaaSSaaS). It was founded in 2015 by Joseph Geraci. The company also entered into a joint venture with Juvenescence AI in 2018 under the name of NetraPharma, which focuses on establishing a computational drug discovery platform. Netramark is headquartered in Toronto, Ontario, Canada.
Netramark is a company developing machine learning-based software-as-a-service (SaaS). It was founded in 2015 by Joseph Geraci. The company also entered into a joint venturejoint venture with Juvenescence AI in 2018 under the name of NetraPharma, which focuses on establishing a computational drug discovery platform. Netramark is headquartered in Toronto, Ontario, Canada.
Netramark's services are composed of its three proprietary technologies: Netraplay, NetraAI, and DeepCrush. Netraplay functions as an interface that allows users to determine and manipulate data inputs and outputs through the use of augmented intelligence. NetraAI is a machine learningmachine learning tool intended to analyze small datasets, although when DeepCrush's functionality is activated, it is able to analyze datasets of all sizes and classify them based on identified correlates. In Netramark's NetraPharma venture, all of these technologies are employed alongside NetraHealthAtlas, a repository of pharmacological-related data.
Netramark is a company developing machine learning-based software-as-a-service (SaaS). It was founded in 2015 by Joseph Geraci. The company also entered into a joint venture with Juvenescence AI in 2018 under the name of NetraPharma, which focuses on establishing a computational drug discovery platform. Netramark is headquartered in Toronto, OntarioOntario, Canada.
A company using quantum machine learning to help pharmaceutical companies with clinical trials and
NetraMark is a Toronto-based machine learning software company founded by Joseph Geraci in 2015.
Netramark is a company developing machine learning-based software-as-a-service (SaaS). It was founded in 2015 by Joseph Geraci. The company also entered into a joint venture with Juvenescence AI in 2018 under the name of NetraPharma, which focuses on establishing a computational drug discovery platform. Netramark is headquartered in Toronto, Ontario, Canada.
Netramark's services are composed of its three proprietary technologies: Netraplay, NetraAI, and DeepCrush. Netraplay functions as an interface that allows users to determine and manipulate data inputs and outputs through the use of augmented intelligence. NetraAI is a machine learning tool intended to analyze small datasets, although when DeepCrush's functionality is activated, it is able to analyze datasets of all sizes and classify them based on identified correlates. In Netramark's NetraPharma venture, all of these technologies are employed alongside NetraHealthAtlas, a repository of pharmacological-related data.